Logo image of IFRX

INFLARX NV (IFRX) Stock Fundamental Analysis

USA - NASDAQ:IFRX - NL0012661870 - Common Stock

1.58 USD
+0.2 (+14.49%)
Last: 10/3/2025, 8:00:02 PM
1.61 USD
+0.03 (+1.9%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, IFRX scores 2 out of 10 in our fundamental rating. IFRX was compared to 536 industry peers in the Biotechnology industry. IFRX may be in some trouble as it scores bad on both profitability and health. IFRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IFRX has reported negative net income.
IFRX had a negative operating cash flow in the past year.
In the past 5 years IFRX always reported negative net income.
In the past 5 years IFRX always reported negative operating cash flow.
IFRX Yearly Net Income VS EBIT VS OCF VS FCFIFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

IFRX has a Return On Assets (-61.67%) which is comparable to the rest of the industry.
IFRX has a Return On Equity (-79.40%) which is in line with its industry peers.
Industry RankSector Rank
ROA -61.67%
ROE -79.4%
ROIC N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
IFRX Yearly ROA, ROE, ROICIFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IFRX Yearly Profit, Operating, Gross MarginsIFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IFRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IFRX has more shares outstanding
IFRX has a worse debt/assets ratio than last year.
IFRX Yearly Shares OutstandingIFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IFRX Yearly Total Debt VS Total AssetsIFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.42, we must say that IFRX is in the distress zone and has some risk of bankruptcy.
IFRX has a Altman-Z score of -4.42. This is comparable to the rest of the industry: IFRX outperforms 41.79% of its industry peers.
IFRX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IFRX has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.42
ROIC/WACCN/A
WACC7.26%
IFRX Yearly LT Debt VS Equity VS FCFIFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

IFRX has a Current Ratio of 4.10. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.
IFRX's Current ratio of 4.10 is in line compared to the rest of the industry. IFRX outperforms 46.64% of its industry peers.
IFRX has a Quick Ratio of 3.78. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.
IFRX's Quick ratio of 3.78 is in line compared to the rest of the industry. IFRX outperforms 46.08% of its industry peers.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.78
IFRX Yearly Current Assets VS Current LiabilitesIFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

IFRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
IFRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.69%.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)54.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%550%

3.2 Future

The Earnings Per Share is expected to grow by 8.79% on average over the next years. This is quite good.
IFRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.39% yearly.
EPS Next Y15.34%
EPS Next 2Y11.28%
EPS Next 3Y6.31%
EPS Next 5Y8.79%
Revenue Next Year-74.12%
Revenue Next 2Y84.57%
Revenue Next 3Y95.58%
Revenue Next 5Y88.39%

3.3 Evolution

IFRX Yearly Revenue VS EstimatesIFRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
IFRX Yearly EPS VS EstimatesIFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IFRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IFRX Price Earnings VS Forward Price EarningsIFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IFRX Per share dataIFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.28%
EPS Next 3Y6.31%

More info and screens

0

5. Dividend

5.1 Amount

IFRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INFLARX NV

NASDAQ:IFRX (10/3/2025, 8:00:02 PM)

After market: 1.61 +0.03 (+1.9%)

1.58

+0.2 (+14.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners24.95%
Inst Owner Change-3.42%
Ins Owners6.38%
Ins Owner ChangeN/A
Market Cap107.05M
Analysts84.29
Price Target4.23 (167.72%)
Short Float %1.2%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.72%
Min EPS beat(2)-11.29%
Max EPS beat(2)30.73%
EPS beat(4)2
Avg EPS beat(4)17.61%
Min EPS beat(4)-17.65%
Max EPS beat(4)68.63%
EPS beat(8)4
Avg EPS beat(8)9.71%
EPS beat(12)8
Avg EPS beat(12)18.17%
EPS beat(16)11
Avg EPS beat(16)18.5%
Revenue beat(2)0
Avg Revenue beat(2)-61.89%
Min Revenue beat(2)-100%
Max Revenue beat(2)-23.79%
Revenue beat(4)1
Avg Revenue beat(4)-43.99%
Min Revenue beat(4)-100.86%
Max Revenue beat(4)48.71%
Revenue beat(8)1
Avg Revenue beat(8)-70.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.33%
PT rev (3m)-21.62%
EPS NQ rev (1m)4.36%
EPS NQ rev (3m)14.93%
EPS NY rev (1m)0.4%
EPS NY rev (3m)7.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-39.22%
Revenue NY rev (1m)10.89%
Revenue NY rev (3m)-16.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 558.03
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.67%
ROE -79.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.82%
Cap/Sales 27.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.78
Altman-Z -4.42
F-Score3
WACC7.26%
ROIC/WACCN/A
Cap/Depr(3y)17.06%
Cap/Depr(5y)14.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y15.34%
EPS Next 2Y11.28%
EPS Next 3Y6.31%
EPS Next 5Y8.79%
Revenue 1Y (TTM)54.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%550%
Revenue Next Year-74.12%
Revenue Next 2Y84.57%
Revenue Next 3Y95.58%
Revenue Next 5Y88.39%
EBIT growth 1Y2.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.02%
EBIT Next 3Y-0.62%
EBIT Next 5YN/A
FCF growth 1Y-42.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.41%
OCF growth 3YN/A
OCF growth 5YN/A